BACKGROUND: Black patients with myocardial infarction (MI) have worse outcomes than white patients, including higher mortality rates, more angina, and worse quality of life. The Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status (TRIUMPH) study was designed to examine whether racial differences in socioeconomic, clinical, genetic, metabolic, biomarker, or treatment characteristics mediate observed disparities in outcomes. METHODS AND RESULTS: Between April 11, 2005, and December 31, 2008, 31 567 patients with MI were prospectively screened; 6152 had an eligible MI, and 4340 (71%) were enrolled from 24 US centers. Consenting patients had detailed chart abstractions of their medical history and processes of inpatient care, supplemented with a detailed baseline interview. Detailed genetic and metabolic data were obtained at hospital discharge in 2979 (69%) and 3013 patients (69%), respectively. In a subset of patients, blood and urine samples were obtained at 1 month (obtained in 27% of survivors) and blood samples at 6 months (obtained in 19% of survivors). Centralized follow-up interviews sought to quantify patients' postdischarge care and outcomes, with a focus on their health status (symptoms, function, and quality of life). At 1, 6, and 12 months, 23%, 27%, and 24%, respectively, were lost to follow-up. Vital status was available for 99% of patients at 12 months. CONCLUSIONS: TRIUMPH is a novel MI registry with detailed information on patients' sociodemographic, clinical, treatment, health status, metabolic, and genetic characteristics. The wealth of patient data collected in TRIUMPH will provide unique opportunities to examine factors that may mediate racial differences in mortality and health status after MI and the complex interactions between genetic and environmental determinants of post-MI outcomes.
BACKGROUND: Black patients with myocardial infarction (MI) have worse outcomes than white patients, including higher mortality rates, more angina, and worse quality of life. The Translational Research Investigating Underlying Disparities in Acute Myocardial InfarctionPatients' Health Status (TRIUMPH) study was designed to examine whether racial differences in socioeconomic, clinical, genetic, metabolic, biomarker, or treatment characteristics mediate observed disparities in outcomes. METHODS AND RESULTS: Between April 11, 2005, and December 31, 2008, 31 567 patients with MI were prospectively screened; 6152 had an eligible MI, and 4340 (71%) were enrolled from 24 US centers. Consenting patients had detailed chart abstractions of their medical history and processes of inpatient care, supplemented with a detailed baseline interview. Detailed genetic and metabolic data were obtained at hospital discharge in 2979 (69%) and 3013 patients (69%), respectively. In a subset of patients, blood and urine samples were obtained at 1 month (obtained in 27% of survivors) and blood samples at 6 months (obtained in 19% of survivors). Centralized follow-up interviews sought to quantify patients' postdischarge care and outcomes, with a focus on their health status (symptoms, function, and quality of life). At 1, 6, and 12 months, 23%, 27%, and 24%, respectively, were lost to follow-up. Vital status was available for 99% of patients at 12 months. CONCLUSIONS: TRIUMPH is a novel MI registry with detailed information on patients' sociodemographic, clinical, treatment, health status, metabolic, and genetic characteristics. The wealth of patient data collected in TRIUMPH will provide unique opportunities to examine factors that may mediate racial differences in mortality and health status after MI and the complex interactions between genetic and environmental determinants of post-MI outcomes.
Authors: C P Cannon; A Battler; R G Brindis; J L Cox; S G Ellis; N R Every; J T Flaherty; R A Harrington; H M Krumholz; M L Simoons; F J Van De Werf; W S Weintraub; K R Mitchell; S L Morrisson; R G Brindis; H V Anderson; D S Cannom; W R Chitwood; J E Cigarroa; R L Collins-Nakai; S G Ellis; R J Gibbons; F L Grover; P A Heidenreich; B K Khandheria; S B Knoebel; H L Krumholz; D J Malenka; D B Mark; C R Mckay; E R Passamani; M J Radford; R N Riner; J B Schwartz; R E Shaw; R J Shemin; D B Van Fossen; E D Verrier; M W Watkins; D R Phoubandith; T Furnelli Journal: J Am Coll Cardiol Date: 2001-12 Impact factor: 24.094
Authors: David D McManus; Jane S Saczynski; Darleen Lessard; Molly E Waring; Jeroan Allison; David C Parish; Robert J Goldberg; Arlene Ash; Catarina I Kiefe Journal: Am J Cardiol Date: 2015-12-02 Impact factor: 2.778
Authors: Faraz Kureshi; Ali Shafiq; Suzanne V Arnold; Kensey Gosch; Tracie Breeding; Ashwath S Kumar; Philip G Jones; John A Spertus Journal: Clin Cardiol Date: 2016-11-07 Impact factor: 2.882
Authors: Suzanne V Arnold; Joshua M Stolker; Kasia J Lipska; Philip G Jones; John A Spertus; Darren K McGuire; Silvio E Inzucchi; Abhinav Goyal; Thomas M Maddox; Marcus Lind; Divya Gumber; Supriya Shore; Mikhail Kosiborod Journal: Circ Cardiovasc Qual Outcomes Date: 2015-04-21
Authors: Rachel P Dreyer; Kumar Dharmarajan; Kevin F Kennedy; Philip G Jones; Viola Vaccarino; Karthik Murugiah; Sudhakar V Nuti; Kim G Smolderen; Donna M Buchanan; John A Spertus; Harlan M Krumholz Journal: Circulation Date: 2017-02-07 Impact factor: 29.690
Authors: Sharon Cresci; Jeremiah P Depta; Petra A Lenzini; Allie Y Li; David E Lanfear; Michael A Province; John A Spertus; Richard G Bach Journal: Circ Cardiovasc Genet Date: 2014-04-24
Authors: Suzanne V Arnold; Kasia J Lipska; Yan Li; Darren K McGuire; Abhinav Goyal; John A Spertus; Mikhail Kosiborod Journal: Am Heart J Date: 2014-07-11 Impact factor: 4.749
Authors: Krishna K Patel; Suzanne V Arnold; Philip G Jones; Mohammed Qintar; Karen P Alexander; John A Spertus Journal: Am J Cardiol Date: 2018-01-10 Impact factor: 2.778